
SEQUENCE LISTING


<110> CELLECTIS

<120> CS1 SPECIFIC MULTI-CHAIN CHIMERIC ANTIGEN RECEPTOR

<130> P81501739PCT00

<160> 22

<170> PatentIn version 3.5



<210>  1

<211>  25
<212>  PRT
<213>  homo sapiens

<220>
<223>  Fc Receptor for IgE, alpha chain, signal peptide

<400>  1
Met Ala Pro Ala Met Glu Ser Pro Thr Leu Leu Cys Val Ala Leu Leu 
1               5                   10                  15      


Phe Phe Ala Pro Asp Gly Val Leu Ala 
            20                  25  


<210>  2

<211>  45
<212>  PRT
<213>  homo sapiens

<220>
<223>  CD8a-hinge

<400>  2
Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala 
1               5                   10                  15      


Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly 
            20                  25                  30          


Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp 
        35                  40                  45  


<210>  3

<211>  15
<212>  PRT
<213>  artificial sequence
<220>
<223>  description of artificial sequence: synthetic oligopeptide

<220>
<223>  linker for VH and VL fragments of the scFv

<400>  3
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210>  4

<211>  52
<212>  PRT
<213>  homo sapiens

<220>
<223>  Fc Receptor for IgE, alpha chain, transmembrane and intracellular domain

<400>  4
Phe Phe Ile Pro Leu Leu Val Val Ile Leu Phe Ala Val Asp Thr Gly 
1               5                   10                  15      


Leu Phe Ile Ser Thr Gln Gln Gln Val Thr Phe Leu Leu Lys Ile Lys 
            20                  25                  30          


Arg Thr Arg Lys Gly Phe Arg Leu Leu Asn Pro His Pro Lys Pro Asn 
        35                  40                  45              


Pro Lys Asn Asn 
    50          


<210>  5

<211>  215
<212>  PRT
<213>  homo sapiens

<220>
<223>  Fc Receptor for IgE, beta chain, without ITAM

<400>  5
Met Asp Thr Glu Ser Asn Arg Arg Ala Asn Leu Ala Leu Pro Gln Glu 
1               5                   10                  15      


Pro Ser Ser Val Pro Ala Phe Glu Val Leu Glu Ile Ser Pro Gln Glu 
            20                  25                  30          


Val Ser Ser Gly Arg Leu Leu Lys Ser Ala Ser Ser Pro Pro Leu His 
        35                  40                  45              


Thr Trp Leu Thr Val Leu Lys Lys Glu Gln Glu Phe Leu Gly Val Thr 
    50                  55                  60                  


Gln Ile Leu Thr Ala Met Ile Cys Leu Cys Phe Gly Thr Val Val Cys 
65                  70                  75                  80  


Ser Val Leu Asp Ile Ser His Ile Glu Gly Asp Ile Phe Ser Ser Phe 
                85                  90                  95      


Lys Ala Gly Tyr Pro Phe Trp Gly Ala Ile Phe Phe Ser Ile Ser Gly 
            100                 105                 110         


Met Leu Ser Ile Ile Ser Glu Arg Arg Asn Ala Thr Tyr Leu Val Arg 
        115                 120                 125             


Gly Ser Leu Gly Ala Asn Thr Ala Ser Ser Ile Ala Gly Gly Thr Gly 
    130                 135                 140                 


Ile Thr Ile Leu Ile Ile Asn Leu Lys Lys Ser Leu Ala Tyr Ile His 
145                 150                 155                 160 


Ile His Ser Cys Gln Lys Phe Phe Glu Thr Lys Cys Phe Met Ala Ser 
                165                 170                 175     


Phe Ser Thr Glu Ile Val Val Met Met Leu Phe Leu Thr Ile Leu Gly 
            180                 185                 190         


Leu Gly Ser Ala Val Ser Leu Thr Ile Cys Gly Ala Gly Glu Glu Leu 
        195                 200                 205             


Lys Gly Asn Lys Val Pro Glu 
    210                 215 


<210>  6

<211>  42
<212>  PRT
<213>  homo sapiens

<220>
<223>  41BB Intracellular domain

<400>  6
Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met 
1               5                   10                  15      


Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe 
            20                  25                  30          


Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu 
        35                  40          


<210>  7

<211>  41
<212>  PRT
<213>  homo sapiens

<220>
<223>  CD28 Intracellular domain

<400>  7
Arg Ser Lys Arg Ser Arg Gly Gly His Ser Asp Tyr Met Asn Met Thr 
1               5                   10                  15      


Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 
            20                  25                  30          


Pro Arg Asp Phe Ala Ala Tyr Arg Ser 
        35                  40      


<210>  8

<211>  18
<212>  PRT
<213>  homo sapiens

<220>
<223>  Fc Receptor for IgE, gamma chain, signal peptide

<400>  8
Met Ile Pro Ala Val Val Leu Leu Leu Leu Leu Leu Val Glu Gln Ala 
1               5                   10                  15      


Ala Ala 
        


<210>  9

<211>  43
<212>  PRT
<213>  homo sapiens

<220>
<223>  Fc Receptor for IgE, gamma chain, without ITAM

<400>  9
Leu Gly Glu Pro Gln Leu Cys Tyr Ile Leu Asp Ala Ile Leu Phe Leu 
1               5                   10                  15      


Tyr Gly Ile Val Leu Thr Leu Leu Tyr Cys Arg Leu Lys Ile Gln Val 
            20                  25                  30          


Arg Lys Ala Ala Ile Thr Ser Tyr Glu Lys Ser 
        35                  40              


<210>  10

<211>  112
<212>  PRT
<213>  homo sapiens

<220>
<223>  CD3z intracellular domain

<400>  10
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly 
1               5                   10                  15      


Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 
            20                  25                  30          


Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 
        35                  40                  45              


Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 
    50                  55                  60                  


Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 
65                  70                  75                  80  


Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 
                85                  90                  95      


Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 
            100                 105                 110         






<210>  11

<211>  22
<212>  PRT
<213>  artificial sequence

<220>
<223>  description of artificial sequence: synthetic oligopeptide

<220>
<223>  GSG-P2A ribosomal skip peptide

<400>  11
Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val 
1               5                   10                  15      


Glu Glu Asn Pro Gly Pro 
            20          


<210>  12

<211>  21
<212>  PRT
<213>  artificial sequence

<220>
<223>  description of artificial sequence: synthetic oligopeptide

<220>
<223>  GSG-T2A ribosomal skip peptide

<400>  12
Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu 
1               5                   10                  15      


Glu Asn Pro Gly Pro 
            20      


<210>  13

<211>  119
<212>  PRT
<213>  artificial sequence

<220>
<223>  description of artificial sequence: synthetic oligopeptide

<220>
<223>  anti-CS1 Luc63 heavy chain variable region

<400>  13
Glu Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr 
            20                  25                  30          


Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Asn Tyr Thr Pro Ser Leu 
    50                  55                  60                  


Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Pro Asp Gly Asn Tyr Trp Tyr Phe Asp Val Trp Gly Ala Gly 
            100                 105                 110         


Thr Thr Val Thr Val Ser Ser 
        115                 


<210>  14

<211>  107
<212>  PRT
<213>  artificial sequence

<220>
<223>  description of artificial sequence: synthetic oligopeptide

<220>
<223>  anti-CS1 Luc63 light chain variable region

<400>  14
Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Ile Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  15

<211>  120
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-CS1 Luc90 heavy chain variable region

<400>  15
Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Thr Tyr 
            20                  25                  30          


Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Thr Met Ile Ala Thr Arg Ala Met Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Ser Val Thr Val Ser Ser 
        115                 120 


<210>  16

<211>  107
<212>  PRT
<213>  artificial sequence

<220>
<223>  description of artificial sequence: synthetic oligopeptide

<220>
<223>  anti-CS1 Luc90 light chain variable region

<400>  16
Asp Ile Val Met Thr Gln Ser Gln Lys Ser Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ile Thr Gly 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Asn Val Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Leu 
                85                  90                  95      


Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105         


<210>  17

<211>  121
<212>  PRT
<213>  artificial sequence

<220>
<223>  description of artificial sequence: synthetic oligopeptide

<220>
<223>  anti-CS1 Luc34 heavy chain variable region

<400>  17
Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Met Gln Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Ala Ile Tyr Pro Gly Asp Gly Asp Thr Arg Tyr Thr Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Lys Val Tyr Tyr Gly Ser Asn Pro Phe Ala Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ala 
        115                 120     


<210>  18

<211>  107
<212>  PRT
<213>  artificial sequence

<220>
<223>  description of artificial sequence: synthetic oligopeptide

<220>
<223>  anti-CS1 Luc34 light chain variable region

<400>  18
Asp Ile Gln Met Thr Gln Ser Ser Ser Tyr Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Arg Val Thr Ile Thr Cys Lys Ala Ser Asp His Ile Asn Asn Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Ser Thr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  19

<211>  120
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-CS1 LucX1 heavy chain variable region

<400>  19
Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser 
            20                  25                  30          


Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Lys Tyr Asn Gly Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Val Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Thr Met Ile Ala Thr Gly Ala Met Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Ser Val Thr Val Ser Ser 
        115                 120 


<210>  20

<211>  107
<212>  PRT
<213>  artificial sequence

<220>
<223>  description of artificial sequence: synthetic oligopeptide

<220>
<223>  anti-CS1 LucX1 light chain variable region

<400>  20
Glu Thr Thr Val Thr Gln Ser Pro Ala Ser Leu Ser Met Ala Ile Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Arg Cys Ile Thr Ser Thr Asp Ile Asp Asp Asp 
            20                  25                  30          


Met Asn Trp Tyr Gln Gln Lys Pro Gly Glu Pro Pro Lys Leu Leu Ile 
        35                  40                  45              


Ser Glu Gly Asn Thr Leu Arg Pro Gly Val Pro Ser Arg Phe Ser Ser 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Val Phe Thr Ile Glu Asn Met Leu Ser 
65                  70                  75                  80  


Glu Asp Val Ala Asp Tyr Tyr Cys Leu Gln Ser Asp Asn Leu Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  21

<211>  120
<212>  PRT
<213>  artificial sequence

<220>
<223>  description of artificial sequence: synthetic oligopeptide

<220>
<223>  anti-CS1 LucX2 heavy chain variable region

<400>  21
Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser 
            20                  25                  30          


Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Lys Tyr Asn Gly Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Val Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Thr Met Ile Ala Thr Gly Ala Met Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Ser Val Thr Val Ser Ser 
        115                 120 


<210>  22

<211>  108
<212>  PRT
<213>  artificial sequence

<220>
<223>  description of artificial sequence: synthetic oligopeptide

<220>
<223>  anti-CS1 LucX2 light chain variable region

<400>  22
Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Pro 
                85                  90                  95      


Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105             



